The Search for an Effective RSV Vaccine: Where We Stand Today?

 MODIFIED FROM © ISTOCK.COM, MICROVONE

‍

Respiratory Syncytial Virus (RSV) is a common viral illness that affects people of all ages. It is especially dangerous for infants, older adults, and people with weakened immune systems. RSV is highly contagious, and it can spread quickly through respiratory droplets when an infected person coughs or sneezes. The virus causes inflammation of the respiratory tract, leading to symptoms such as coughing, wheezing, and difficulty breathing. In severe cases, RSV can cause pneumonia, bronchiolitis, and even death. Despite decades of research, there is still no effective vaccine for RSV. This is a major concern for healthcare professionals, parents, and anyone who has ever been affected by the virus.

What is RSV and why is it important?

RSV is a respiratory virus that commonly infects children under the age of two. However, it can affect people of all ages, especially in crowded areas such as nursing homes and daycares. RSV can cause mild to severe respiratory illness, and in some cases, it can be life-threatening. Infants and young children are at the highest risk of developing severe RSV infection, which can lead to hospitalization and long-term respiratory problems. Older adults and people with weakened immune systems are also at risk of severe RSV infection.

RSV is a major public health concern, both in developed and developing countries. According to the World Health Organization (WHO), RSV is responsible for an estimated 33.1 million new cases of acute lower respiratory infection (ALRI) in children under the age of five, resulting in 3.2 million hospitalizations and 118,200 deaths worldwide every year. In the United States alone, RSV is responsible for an estimated 57,000 hospitalizations and 2.1 million outpatient visits among children under the age of five every year.

The history of RSV vaccine development

The first attempts to develop an RSV vaccine date back to the 1950s, shortly after the virus was discovered. However, early attempts were unsuccessful, and in some cases, they even made the disease worse when vaccinated individuals were exposed to the virus. In the 1960s, a formalin-inactivated RSV vaccine was developed and tested in clinical trials. However, the vaccine was found to be ineffective and caused severe respiratory illness in some vaccinated children when they were exposed to natural RSV infection.

In the 1980s, a live attenuated RSV vaccine was developed and tested in clinical trials. The vaccine was found to be safe and effective in animal models, but it failed to protect against RSV infection in human trials. In the 1990s, a monoclonal antibody called Palivizumab was developed for the prevention of severe RSV infection in high-risk infants. The antibody was found to be effective in reducing hospitalizations and respiratory illness in infants, but it was expensive and required monthly injections.

Challenges in developing an RSV vaccine

Developing an effective RSV vaccine has proven to be a challenging task, mainly due to the unique characteristics of the virus. RSV is a highly variable virus, with multiple strains circulating in the population. The virus also has a complex replication cycle and can evade the immune system, making it difficult to develop a vaccine that can provide long-lasting protection against all strains of the virus. Additionally, RSV infection can cause both humoral and cellular immune responses, and the exact immune response needed for protection against RSV infection is still not well understood.

Another challenge in developing an RSV vaccine is the risk of vaccine-enhanced disease. This occurs when vaccinated individuals develop more severe disease upon exposure to natural RSV infection. Vaccine-enhanced disease is believed to occur when the vaccine fails to elicit a balanced immune response, leading to an exaggerated immune response upon natural exposure to the virus. This is a major safety concern that needs to be addressed in the development of any RSV vaccine.

Current state of RSV vaccine research

Despite these challenges, researchers continue to work towards developing a safe and effective RSV vaccine. There are currently several promising RSV vaccine candidates in various stages of development, including live attenuated, inactivated, subunit, and viral vector-based vaccines. These vaccines aim to elicit a balanced immune response that can provide long-lasting protection against all strains of RSV.

One promising RSV vaccine candidate is the nanoparticle vaccine developed by Novavax. This vaccine uses a recombinant protein nanoparticle platform to present RSV fusion protein in a way that can elicit a strong immune response. In phase 2 clinical trials, the vaccine was found to be safe and effective in eliciting a strong immune response in healthy adults. The vaccine is currently in phase 3 clinical trials, with results expected in the near future.

Another promising RSV vaccine candidate is the mRNA-based vaccine developed by Moderna. This vaccine uses a novel mRNA platform to encode RSV fusion protein and elicit a strong immune response. In phase 1 clinical trials, the vaccine was found to be safe and effective in eliciting a strong immune response in healthy adults. The vaccine is currently in phase 2 clinical trials, with results expected in the near future.

Promising RSV vaccine candidates

In addition to Novavax and Moderna's vaccines, there are several other promising RSV vaccine candidates in various stages of development. These include:

·        GlaxoSmithKline's (GSK) RSV vaccine, which uses a subunit approach to present RSV fusion protein and elicit a strong immune response. The vaccine has shown promising results in early clinical trials.

·        The University of Texas Medical Branch's (UTMB) RSV vaccine, which uses a viral vector approach to deliver RSV fusion protein and elicit a strong immune response. The vaccine has shown promising results in animal models and is currently in clinical trials.

·        The National Institute of Allergy and Infectious Diseases (NIAID) RSV vaccine, which uses a live attenuated approach to present RSV fusion protein and elicit a strong immune response. The vaccine has shown promising results in animal models and is currently in clinical trials.

Clinical trials for RSV vaccines

As mentioned, several RSV vaccines are currently in clinical trials, with results expected in the near future. Clinical trials are essential to determine the safety and efficacy of any vaccine candidate before it can be approved for use in the general population. Clinical trials typically involve three phases:

·        Phase 1 trials involve a small group of healthy volunteers and aim to determine the safety and dosage of the vaccine candidate.

·        Phase 2 trials involve a larger group of volunteers and aim to determine the vaccine's safety and efficacy in eliciting an immune response.

·        Phase 3 trials involve a large group of volunteers and aim to confirm the vaccine's safety and efficacy in protecting against natural RSV infection.

If the vaccine is found to be safe and effective in all three phases of clinical trials, it can be submitted for regulatory approval and eventual distribution to the general population.

Potential impact of an RSV vaccine

The development of an effective RSV vaccine has the potential to have a significant impact on public health worldwide. An RSV vaccine would reduce the number of hospitalizations and deaths caused by RSV infection, especially in high-risk populations such as infants and older adults. It would also reduce the economic burden of RSV infection on healthcare systems and families.

Furthermore, an RSV vaccine could have a significant impact on global health equity. RSV infection disproportionately affects low-income countries, where access to healthcare and preventive measures such as Palivizumab is limited. An affordable and effective RSV vaccine would provide a much-needed solution to this global health challenge.

RSV prevention strategies

While an RSV vaccine is still in development, there are several preventive measures that individuals can take to reduce the risk of RSV infection. These include:

·        Washing hands frequently with soap and water or alcohol-based hand sanitizer.

·        Covering the mouth and nose when coughing or sneezing.

·        Avoiding close contact with people who are sick.

·        Keeping infants away from crowded areas such as daycares during RSV season.

·        Avoiding smoking and exposure to secondhand smoke.

The importance of continued RSV research

The development of an effective RSV vaccine requires ongoing research and investment. Despite decades of research, there is still much to learn about the immune response to RSV infection and the best approach to developing a safe and effective vaccine. Continued investment in RSV research will be critical to the development of an effective vaccine that can protect against all strains of the virus.

Individuals can also play a role in supporting RSV research. This can be done by supporting organizations that fund RSV research, donating to RSV research initiatives, and participating in clinical trials for RSV vaccines.

Conclusion

RSV is a major public health concern that affects people of all ages, especially infants, older adults, and people with weakened immune systems. Despite decades of research, there is still no effective vaccine for RSV. However, there are several promising RSV vaccine candidates in various stages of development, including the nanoparticle vaccine developed by Novavax and the mRNA-based vaccine developed by Moderna.

The development of an effective RSV vaccine has the potential to have a significant impact on public health worldwide, reducing the number of hospitalizations and deaths caused by RSV infection and providing a solution to this global health challenge. Continued investment in RSV research will be critical to the development of an effective vaccine that can protect against all strains of the virus.